Search

2024 SEP 9 (NewsRx) -- By a News Reporter-Staff News Editor at Cardiovascular Week -- Current study results on type 2 diabetes have been published. According to news reporting originating [...]

Overview Chronic kidney disease, also called chronic kidney failure, involves a gradual loss of kidney function. Your kidneys filter wastes and excess fluids from your blood, which are then removed [...]

Overview Chronic kidney disease, also called chronic kidney failure, involves a gradual loss of kidney function. Your kidneys filter wastes and excess fluids from your blood, which are then removed [...]

Overview Chronic kidney disease, also called chronic kidney failure, involves a gradual loss of kidney function. Your kidneys filter wastes and excess fluids from your blood, which are then removed [...]

Overview Chronic kidney disease, also called chronic kidney failure, involves a gradual loss of kidney function. Your kidneys filter wastes and excess fluids from your blood, which are then removed [...]

2024 JUL 26 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators discuss new findings in chronic kidney disease. According to news reporting from [...]

Key Highlights: * Everest Medicines launched Nefecon (budesonide DR) to treat IgAN in China * Nefecon can delay kidney function deterioration by 66 * Nefecon can delay progression to ESRD [...]

2024 JUN 24 (NewsRx) -- By a News Reporter-Staff News Editor at Cardiovascular Week -- Data detailed on chronic kidney disease have been presented. According to news reporting originating from [...]

Reviews evidence of newer medications, recommends adding to metformin BOSTON, April 19, 2024 /PRNewswire/ -- The American College of Physicians (ACP) today released an update of its 2017 guideline with [...]

APPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with IgAN[sup.1] IgAN is a heterogeneous, progressive, rare kidney disease [...]

(GLOBE NEWSWIRE via COMTEX) -- - APPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with IgAN1 - IgAN [...]

Interwell Provider Network Includes 1,800 Nephrologists Nationwide Committed to Population Health MORGANTOWN, W.Va., March 26, 2024 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=4123829-1&h=3002758546&u=http%3A%2F%2Fwww.wvumedicine.org%2F&a=WVU+Medicine announced today that it has entered into an agreement with https://c212.net/c/link/?t=0&l=en&o=4123829-1&h=3322391009&u=https%3A%2F%2Fwww.interwellhealth.com%2F%3Futm_source%3DOwnedMedia%26utm_medium%3Dpress_release%26utm_campaign%3DCompanyNews%26utm_id%3D2024_CompanyNews%26utm_term%3D%26utm_content%3DWVUMedicine&a=Interwell+Health [...]

The Bayer Group achieved its adjusted guidance for 2023. The firm also reported its financial results for 2023. Sales of prescription medicines (Pharmaceuticals) were level year on year at EUR 18.081 bn. The division's most recent product launches achieved significant gains, with growth rates of 93.6% for the cancer drug Nubeqa and 160.6% for Kerendia, for the treatment of chronic kidney disease associated with type 2 diabetes. The division also posted continued sales growth for the ophthalmology drug Eylea, with an increase of 5.6%, as well as in the Radiology business, which includes the Ultravist, CT Fluid Delivery and Gadovist product families. By contrast, sales declined significantly in China, in part due to pandemic-related developments at the start of the year, and tender procedures for Adalat; on a global level, sales of the cardiovascular drug decreased by 27.2%. In addition, China's anti-corruption campaign in the healthcare sector indirectly had a negative impact on demand in 2H 2024. As expected, sales of the oral anticoagulant Xarelto were also down, falling 6.1% as a result of competitive and pricing pressure from generics. EBITDA before special items at Pharmaceuticals decreased by 11.6% to EUR 5.189 bn. The EBITDA margin before special items declined by 1.8 percentage points to 28.7%. Original source: Bayer, website:http://www.bayer.com/, Copyright Bayer AG 2024., company results; market; CT Fluid Delivery; Eylea; Gadovist; generic pharmaceuticals; iopromide; Kerendia; kidney disorder treatments; nifedipine; Nubeqa; ophthalmic drugs; pharmaceuticals; rivaroxaban; Bayer [...]

2024 MAR 22 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- New study results on chronic kidney disease have been published. According to news [...]

PASADENA: Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-CFB, the company's investigational RNA interference [...]

PASADENA, Calif. -- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-CFB, the company's investigational [...]

Diabetic kidney disease (DKD), which affects around 240 million people with Type 2 diabetes worldwide, is the leading cause of end-stage renal disease, which requires dialysis or kidney transplant for [...]

Results from the real-world ZORA observational multi-country study presented on 2 Nov 2023 at the American Society of Nephrology (ASN) 2023 shows that treating hyperkalaemia (HK) with the potassium binder Lokelma (sodium zirconium cyclosilicate) can allow patients with chronic kidney disease (CKD) or heart failure (HF) to maintain their lifesaving renin-angiotensin-aldosterone system inhibitor (RAASi) therapy. Analysis showed that patients treated with Lokelma were substantially more likely to maintain guideline-recommended RAASi therapy at 6 months following a hyperkalaemia (HK) episode, compared to patients who were not treated with a potassium binder, the odds were approximately 2.5-times higher. Additional analysis also showed that the risk of progression to end-stage kidney disease (ESKD), diagnosed as chronic kidney disease (CKD) stage 5 or the initiation of dialysis, within 6 months following a hyperkalaemia episode was 73% higher in patients who discontinued RAASi treatment, and 60% higher in patients who down-titrated vs maintained RAASi therapy. This builds on previous data showing that HK-related RAASi reduction increases the risk of cardiorenal events and mortality among patients with CKD or HF. This RWE study indicates an urgent need for improved guideline adherence in managing HK to enable patients to stay on their lifesaving RAASi therapy. Original source: AstraZeneca, website: http://www.astrazeneca.com, Copyright AstraZeneca 2023., research and development; blood disorder treatments; Lokelma; sodium zirconium cyclosilicate; zirconium [...]

Overview Chronic kidney disease, also called chronic kidney failure, involves a gradual loss of kidney function. Your kidneys filter wastes and excess fluids from your blood, which are then removed [...]

This review paper summarizes numerous research studies that address the role of kidney cholesterol and lipid accumulation in the development and progression of chronic kidney disease (CKD). ZyVersa's Cholesterol Efflux [...]

Overview Chronic kidney disease, also called chronic kidney failure, involves a gradual loss of kidney function. Your kidneys filter wastes and excess fluids from your blood, which are then removed [...]

Overview Chronic kidney disease, also called chronic kidney failure, involves a gradual loss of kidney function. Your kidneys filter wastes and excess fluids from your blood, which are then removed [...]

2024 FEB 2 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Researchers detail new data in chronic kidney disease. According to news originating from [...]

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending Jardiance (empagliflozin) for the treatment of adults with chronic kidney disease (CKD), Boehringer Ingelheim and Eli Lilly and Company announced on 23 Jun 2023. Empagliflozin is currently indicated for the treatment of heart failure and type 2 diabetes in adults. When approved, empagliflozin's indications in the EU will include adults living with CKD, paving the way for an approach to managing the amplified risks of interconnected cardio-renal-metabolic conditions. The EMPA-KIDNEY Phase III trial included 6609 adults across the spectrum of CKD severity with a wide range of underlying causes and co-morbidities, making EMPA-KIDNEY the largest and broadest dedicated selective sodium-glucose cotransporter 2 (SGLT2) inhibitor trial in CKD to date. Empagliflozin demonstrated a significant kidney and cardiovascular benefit in adults with CKD, reducing the relative risk of kidney disease progression or cardiovascular death by 28% versus placebo. Original source: Boehringer Ingelheim, website: http://www.boehringer-ingelheim.com/, Copyright Boehringer Ingelheim GmbH 2023., regulations and rulings; research and development; antidiabetics; cardiovascular drugs; empagliflozin; Jardiance; kidney disorder treatments; Boehringer Ingelheim; Eli Lilly and [...]

Overview Chronic kidney disease, also called chronic kidney failure, involves a gradual loss of kidney function. Your kidneys filter wastes and excess fluids from your blood, which are then removed [...]

About 15% of adults in the U.S. are https://www.cdc.gov/kidneydisease/basics.html#:~:text=15%25%20of%20US%20adults%20are,number%20of%20red%20blood%20cells to have chronic kidney disease -- that's about 37 million people. What if those people could be treated with medication that [...]